Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab

Journal of Crohn's and Colitis

Volumn 6, Issue 4, 2012, Pages 483-487

  Desales, Ana L ^a   Mendez Navarro, Jorge ^a   Méndez Tovar, Luis J ^a   Ortiz Olvera, Nayeli X ^a   Cullen, Garret ^b   Ocampo, Joaquín ^a   Lemus, Willian ^a   Tun, Amina E ^a   Mayoral Zavala, Arturo ^a   Dehesa Violante, Margarita ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Adalimumab; ; Anti TNF; Crohn's disease; ; Opportunistic infections; ; PCP; ; Pneumonia;

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; IMIPENEM; MESALAZINE; PREDNISONE;

ABDOMINAL PAIN; ADULT; APHTHOUS ULCER; ARTHRALGIA; ARTICLE; BIOPSY TECHNIQUE; BRONCHOSCOPY; CASE REPORT; CHRONIC DIARRHEA; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; FEVER; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYALGIA; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTOSIS; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TRACHEOBRONCHIAL TOILET; VOMITING; WEIGHT REDUCTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860125381     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.10.012     Document Type: Article

References (26)

1. Russian D.A., Levine S.J. Pneumocystis carinii pneumonia in patients without HIV infection. Am J Med Sci 2001, 321:56-65.
2. Thomas C.F., Limper A.H. Pneumocystis pneumonia. N Engl J Med 2004, 350:2487-2498.
3. Cheng C.Y., Chen M.Y., Hsieh S.M., Sheng W.H., Sun H.Y., Lo Y.C., et al. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2010, 10:126-133.
4. Sands B.E. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007, 42:16-25.
5. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483.
6. Rutgeerts P., Assche G., Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593-1610.
7. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
8. Peters J.W., Sattler F.R. Atypical Pneumocystis carinii pneumonia: the potential hazards of empiric treatment. South Med J 1983, 76:800-803.
9. Seddik M., Meliez H., Seguy D., Viget N., Cortot A., Colombel J.F. Pneumocystis carini pneumonia following initiation of infliximab and azathioprine therapy with Crohn's disease. Inflamm Bowel Dis 2004, 49:1438-1460.
10. Kaur N., Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007, 52:1481-1484.
11. Lee T.W., Fedorak R.N. Tumor necrosis factor α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am 2010, 543-557.
12. Tsiodras S., Samonis G., Boumpas D.T., Kontoyiannis D.P. Fungal infections complicating tumor necrosis factor α blockade therapy. Mayo Clin Proc 2008, 83:181-194.
13. Reenaers C., Louis E., Belaiche J. Current directions of biologic therapies in inflammatory bowel diseases. Ther Adv Gastroenterol 2010, 3:99-106.
14. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
15. Yamamoto-Furusho J.K., Bosques-Padilla F. Consenso mexicano sobre el uso de agentes anti-TNF-α en el tratamiento de la enfermedad inflamatoria intestinal. Rev Gastroenterol Mex 2009, 74:265-278.
16. Clark M., Colombel J.F., Feagan B.C., Fedorak R.N., Hanauer S.B., Kamm M.A., et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007, 133:312-339.
17. Méndez-Navarro J., Corey K.E., Zheng H., Barlow L.L., Jang J.Y., Lin W., et al. Hepatitis B Screening, prophylaxis and reactivation in the era of rituximab-based chemotherapy. Liver Int 2011, 31:330-339.
18. Verhelst X., Orlent H., Colle I., Geerts A., De Vos M., Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatorid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 2010, 22:494-499.
19. Colombel J.F., Sandborn W.J., Panaccione R., Robinson A.M., Lau W., Li J., et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009, 15:1308-1319.
20. Komano Y., Harigai M., Koike R., Sugiyama H., Ogawa J., Saito K., et al. Pneumocystis jiroveci pneumonia in patients with Rheumatoid Arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 2009, 61:305-312.
21. Itaba S., Iwasa T., Sadamoto Y., Nasu T., Misawa T., Inoue K., et al. Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid and azathioprine in a patient with Crohn's disease. Dig Dis Sci 2007, 52:1438-1441.
22. Lawrance I.C., Radford-Smith G.L., Bampton P.A., Andrews J.M., Tan P.K., Croft A., et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010, 25:1732-1738.
23. Cottone M., Kohn A., Daperno M., Armuzzi A., Guidi L., DD́Inca R., et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:30-35.
24. Roblot F. Management of Pneumocystis pneumonia in patients with inflammatory disorders. Expert Rev Anti Infect Ther 2005, 3:1098-1107.
25. Helweg-Larsen J., Benfield T., Atzori C., Miller R.F. Clinical efficacy of first-and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. JAC 2009, 64:1282-1290.
26. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P, DD́Haens G., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.